AstraZeneca Iressa Response Working, Company Says: Docs Move To Tarceva
Executive Summary
AstraZeneca's efforts to promote Genentech/OSI's Tarceva as the first-choice epidermal growth factor receptor therapy are working, the company told FDA's Oncologic Drugs Advisory Committee March 4
You may also be interested in...
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005
Zarnestra Phase III Trial May Lack Sufficient Power To Show Survival Benefit
An ongoing Phase III trial of Johnson & Johnson's acute myeloid leukemia therapy Zarnestra may lack sufficient power to show a survival benefit, the FDA Oncologic Drugs Advisory Committee biostatistician suggested May 6